Free tool
Drug Trial Radar: Gastroenterology and liver
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
13
Active, not recruiting, industry sponsors, Gastroenterology and liver, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed158
13 trials
Showing 1 to 13, recently updated first.
- Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)Pivotal-lookingActive, not recruiting
IpsenIndustry
NCT04526665 · 161 participants · Start Sep 24, 2020 · Primary completion Jun 1, 2023
Drug: Elafibranor 80mg; Placebo · For: Primary Biliary Cirrhosis
Sites: Chandler, Arizona; Los Angeles, California; Sacramento, California · 115 sites in all
- A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )Pivotal-lookingActive, not recruiting
Inventiva PharmaIndustry
NCT04849728 · 1,000 participants (planned) · Start Aug 19, 2021 · Primary completion Sep 29, 2026
Drug: IVA337; Placebo · For: NASH - Nonalcoholic Steatohepatitis
Sites: Birmingham, Alabama; Dothan, Alabama; Madison, Alabama · 459 sites in all
- Efficacy and Safety of Tezepelumab in Patients With Eosinophilic EsophagitisPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05583227 · 368 participants · Start Nov 10, 2022 · Primary completion Jul 14, 2026
Drug: Tezepelumab; Tezepelumab · For: Eosinophilic Esophagitis
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Angeles, California · 124 sites in all
- A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)Pivotal-lookingActive, not recruiting
IpsenIndustry
NCT06730061 · 18 participants · Start Jan 16, 2025 · Primary completion Dec 17, 2026
Drug: Elafibranor · For: Primary Biliary Cholangitis
Sites: Chiba, Japan; Fukushima, Japan; Hiroshima, Japan · 16 sites in all
- Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)Pivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04822181 · 1,205 participants · Start Apr 1, 2021 · Primary completion Apr 25, 2029
Drug: Semaglutide; Placebo · For: Non-alcoholic Steatohepatitis
Sites: Huntsville, Alabama; Chandler, Arizona; Peoria, Arizona · 558 sites in all
- Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoEPivotal-lookingActive, not recruiting
Dr. Falk Pharma GmbHIndustry
NCT06596252 · 308 participants (planned) · Start May 21, 2021 · Primary completion Dec 2026
Drug: Budesonide · For: Eosinophilic Esophagitis
Sites: Scottsdale, Arizona; Little Rock, Arkansas; La Jolla, California · 21 sites in all
- A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)Pivotal-lookingActive, not recruiting
Madrigal Pharmaceuticals, Inc.Industry
NCT05500222 · 845 participants (planned) · Start Aug 26, 2022 · Primary completion Dec 2026
Drug: Resmetirom; Placebo · For: NASH; Cirrhosis, Liver
Sites: Birmingham, Alabama; Chandler, Arizona; Peoria, Arizona · 141 sites in all
- A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and FibrosisPivotal-lookingActive, not recruiting
Madrigal Pharmaceuticals, Inc.Industry
NCT03900429 · 1,759 participants · Start Mar 28, 2019 · Primary completion Jan 2028
Drug: MGL-3196; Placebo · For: NASH - Nonalcoholic Steatohepatitis
Sites: Birmingham, Alabama; Chandler, Arizona; Glendale, Arizona · 247 sites in all
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)Pivotal-lookingActive, not recruiting
Madrigal Pharmaceuticals, Inc.Industry
NCT04951219 · 810 participants · Start Jul 9, 2021 · Primary completion Mar 2027
Drug: Resmetirom · For: Non-Alcoholic Fatty Liver Disease
Sites: Birmingham, Alabama; Chandler, Arizona; Glendale, Arizona · 76 sites in all
- A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)Pivotal-lookingActive, not recruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06884293 · 479 participants · Start May 9, 2025 · Primary completion Dec 31, 2026
Drug: IBI362; semaglutide · For: Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Sites: Beijing, China
- Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary CholangitisPivotal-lookingActive, not recruiting
Zydus Therapeutics Inc.Industry
NCT06427395 · 102 participants · Start Jul 16, 2024 · Primary completion Apr 18, 2027
Drug: Saroglitazar Magnesium 1 mg · For: Primary Biliary Cholangitis
Sites: Los Angeles, California; Pasadena, California; Sacramento, California · 28 sites in all
- Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT03301506 · 340 participants (planned) · Start Dec 12, 2017 · Primary completion Nov 2028
Drug: Seladelpar 5 mg Capsule; Seladelpar 10 mg Capsule · For: Primary Biliary Cirrhosis
Sites: Little Rock, Arkansas; Palo Alto, California; Pasadena, California · 109 sites in all
- A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Pivotal-lookingActive, not recruiting
Akero Therapeutics, IncIndustry
NCT06161571 · 700 participants (planned) · Start Nov 10, 2023 · Primary completion Mar 3, 2026
Drug: Efruxifermin; Placebo · For: NASH/MASH; NAFLD/MASLD
Sites: Birmingham, Alabama; Chandler, Arizona; Flagstaff, Arizona · 211 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.